Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Wintrich, S"'
Autor:
Frank P; Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland. pauline.frank@novartis.com., Olshan A; Olshan Patient Relations Inc, Stamford, CT, USA., Iraca T; Myelodysplastic Syndromes Foundation US, Yardville, NJ, USA., Anthony C; Aplastic Anemia and Myelodysplasia Association Canada, King City, ON, Canada., Wintrich S; MDS UK Patient Support Group, London, UK., Sasse E; Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland.
Publikováno v:
Oncology and therapy [Oncol Ther] 2024 Mar; Vol. 12 (1), pp. 97-114. Date of Electronic Publication: 2023 Dec 07.
Autor:
Pemberton-Whiteley Z; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland.; Leukaemia Care, Worcester, United Kingdom., Nier S; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland., Geissler J; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland.; LeukaNET e.V., Riemerling, Germany., Wintrich S; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland.; MDS UK Patient Support Group, United Kingdom., Verhoeven B; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland.; Foundation Hematon, Utrecht, Netherlands., Christensen RO; Acute Leukemia Advocates Network (ALAN), Bern, Switzerland.; LyLe Patientforeningenen for Lymfekræft Leukæmi og MDS, Sealand Region, Denmark., Salek S; University of Hertfordshire, Hatfield, United Kingdom., Oliva EN; Division of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy., Ionova T; National Medical Surgical Centre and Multinational Centre for Quality of Life Research, Saint Petersburg, Russian Federation., Bradley J; Quality Health Ltd, an IQVIA company, Derbyshire, United Kingdom.
Publikováno v:
Journal of patient-centered research and reviews [J Patient Cent Res Rev] 2023 Jan 17; Vol. 10 (1), pp. 21-30. Date of Electronic Publication: 2023 Jan 17 (Print Publication: 2023).
Autor:
Vijenthira A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Starkman R; New York Medical College, Valhalla, New York, USA., Lin Y; Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Stanworth SJ; Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Bowen D; Department of Hematology, Leeds Teaching Hospitals, Leeds, United Kingdom., Harrison L; MDS Foundation Inc., Yardville, New Jersey, USA., Wintrich S; MDS UK Patient Support Group, London, UK., Callum J; Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Buckstein R; MDS Research Program, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada.
Publikováno v:
Transfusion [Transfusion] 2022 Jul; Vol. 62 (7), pp. 1355-1364. Date of Electronic Publication: 2022 Jun 10.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCKR.37 /20170904/
Einleitung: Transition ist der geordnete Übergang aus der kinderfachärztlichen Betreuung in die Erwachsenenmedizin. Es herrscht oftmals der Eindruck, es findet kein geordneter Übergang statt und die Patientin/ der Patient ist unzureichend vorberei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4ab3d7014aad9a2cdd88d8aabd61e53
Publikováno v:
43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20150902-20150905; Bremen; DOCKR.24 /20150901/
Einleitung: Die systemische juvenile idiopathische Arthritis (sJIA) und das familiäre Mittelmeerfieber (FMF) zeigen mit Fieber, Arthritis, Exanthem, generalisierter Lymphadenopathie und Serositis viele Gemeinsamkeiten. Therapieoptionen bei der sJIA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5063db0e78c7b514302ccba8d47e31c6
Publikováno v:
Zeitschrift für Rheumatologie; Oct2018, Vol. 77 Issue 8, p677-684, 8p
Autor:
Niscola, Pasquale1 (AUTHOR) pasquale.niscola@aslroma2.it, Gianfelici, Valentina1 (AUTHOR), Giovannini, Marco1 (AUTHOR), Piccioni, Daniela1 (AUTHOR), Mazzone, Carla1 (AUTHOR), de Fabritiis, Paolo1 (AUTHOR)
Publikováno v:
Cancers. Apr2024, Vol. 16 Issue 8, p1563. 19p.
Autor:
Thanarajasingam G; Division of Haematology, Mayo Clinic, Rochester, MN, USA. Electronic address: thanarajasingam.gita@mayo.edu., Minasian LM; National Cancer Institute, National Institutes of Health, Department of Health & Human Services, Bethesda, MD, USA., Baron F; Division of Haematology, University of Liege, Liege, Belgium., Cavalli F; Oncology Institute of Southern Switzerland, Bellinzona, Switzlerand., De Claro RA; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Dueck AC; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA., El-Galaly TC; Department of Haematology, Aalborg University Hospital, Aalborg Denmark., Everest N; Haematology Clinical Evaluation Unit, Therapeutic Goods Administration, Department of Health, Symondston, ACT, Australia., Geissler J; Leukaemia Patient Advocates Foundation, Bern, Switzerland., Gisselbrecht C; Haemato-Oncology Department, Hopital Saint-Louis, Paris Diderot University VII, Paris, France., Gribben J; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Horowitz M; Division of Haematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Ivy SP; National Cancer Institute, National Institutes of Health, Department of Health & Human Services, Bethesda, MD, USA., Jacobson CA; Division of Haematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Keating A; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada., Kluetz PG; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Krauss A; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Kwong YL; Department of Haematology and Haematologic Oncology, University of Hong Kong, Hong Kong, China., Little RF; National Cancer Institute, National Institutes of Health, Department of Health & Human Services, Bethesda, MD, USA., Mahon FX; University of Bordeaux Cancer Institute, Bordeaux, France., Matasar MJ; Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mateos MV; Haematology Department, University Hospital of Salamanca-IBSAL, Salamanca, Spain., McCullough K; Division of Haematology, Mayo Clinic, Rochester, MN, USA., Miller RS; CancerLinQ, American Society of Clinical Oncology, Alexandria, VA, USA., Mohty M; Haematology and Cellular Therapy Department, Saint-Antoine Hospital, University Pierre & Marie Curie, Paris, France., Moreau P; University Hospital of Nantes, Nantes, France., Morton LM; National Cancer Institute, National Institutes of Health, Department of Health & Human Services, Bethesda, MD, USA., Nagai S; University of Tokyo, Tokyo, Japan; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Rule S; Plymouth University Medical School, Plymouth, UK., Sloan J; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Sonneveld P; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Thompson CA; Division of Haematology, Mayo Clinic, Rochester, MN, USA., Tzogani K; European Medicines Agency, London, UK., van Leeuwen FE; Netherlands Cancer Institute, Amsterdam, Netherlands., Velikova G; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK., Villa D; Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada., Wingard JR; Division of Haematology & Oncology, University of Florida College of Medicine, Gainesville, FL, USA., Wintrich S; Myelodysplastic Syndrome (MDS) Alliance and MDS UK Patient Support Group, London, UK., Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Royal Melbourne Hospital, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia., Habermann TM; Division of Haematology, Mayo Clinic, Rochester, MN, USA.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2018 Nov; Vol. 5 (11), pp. e563-e598. Date of Electronic Publication: 2018 Jun 18.